Executive Commitee

The Chief Executive Officer (CEO) is responsible for the operative and results-oriented management of the Siegfried Group and its divisions. Subject to the competencies and directives of the Board of Directors, the CEO is responsible for the achievement of the corporate goals as well as the management of the subordinate Group companies. 

From left to right: Arnoud Middel, Wolfgang Wienand, Marianne Späne, Reto Suter, Rudolf Hanko, René Imwinkelried
Rudolf Hanko, Ph.D., Chief Executive Officer

Rudolf Hanko (1955) was appointed CEO of Siegfried in May 2009. Prior to joining Siegfried, he worked in the chemical-pharmaceutical industry in various management positions, at Evonik Industries AG (Germany) as Head of Exclusive Synthesis & Amino Acids. Rudolf Hanko also headed the pharmaceutical division of Bayer AG as Head of Chemical Research and as General Manager of the fine chemicals division.

Rudolf Hanko received his Ph.D. in chemistry from the University of Göttingen (Germany) and completed post-doctoral studies at the Max Planck Institute (Germany).

Rudolf Hanko is a German citizen.

Reto Suter, Ph.D., Chief Financial Officer

Reto Suter (1971) joined Siegfried on May 1, 2017, as Chief Financial Officer. Over the last 16 years, he has held a range of responsible positions in industry as well as in finance and private equity. In his last post as COO, CIO and Board Member, Reto Suter was responsible for overseeing the public takeover and subsequent delisting and restructuring of Lonrho, a long-established company headquartered in London (UK) and Johannesburg (SA).

Reto Suter studied economics at the University of Zurich and the University of Washington in Seattle and took his doctorate in banking and finance at the University of Zurich.

Reto Suter is a Swiss Citizen.

René Imwinkelried, Ph.D., Head Global Operations

Rene Imwinkelried (1957) was appointed Head of Technical Operations of the Siegfried Group per November 1, 2016. From 2012 to 2016, Rene Imwinkelried was responsible for the Research & Development of the Siegfried Group.

He holds a Ph.D. in organic chemistry from the ETH Zurich and completed a post-doctoral fellowship at Colorado State University and Harvard University. From 1991 to 2004, he worked in various R&D management positions at Lonza, and as Head of global chemical and physical sciences at US-based Schering-Plough. From 2010 to 2012, he was Head of ”Technical Development Small Molecules” at Roche in Basel.

Rene Imwinkelried is a Swiss citizen.

Arnoud Middel, Head Human Resources Global

Arnoud Middel (1971) joined the Siegfried Group in September 2011 as Head of Human Resources. Previously, he worked for various companies in the field of human resources. From 2003 to 2006, he held a leading position in the human resources department of the Baloise insurance Switzerland. From 2006 to 2008, he was Head HR for the region Continental Europe and Asia of the American industry- and reinsurance group XL-Insurance. From 2008 to 2011, he worked as Head of HR Switzerland and Global Headquarters for Syngenta in Basel (Switzerland).

He completed his studies in biology and biochemistry at the University of Basel (Switzerland).

Arnoud Middel is a Dutch citizen.

Marianne Spaene, Head Business Development & Sales

Marianne Späne (1962) joined the Siegfried Group in 2004 and was appointed Head of Business Development & Sales in March 2010. She headed the Siegfried Generics Division from 2008 to 2010 and was previously responsible for the Classical Generics Business Unit. From 2004 to 2008, Marianne Späne managed the Business Development Department and the Supply Chain for Generics. Prior to joining Siegfried, she worked in logistics, business development and as site manager for Boucheron, a cosmetics company. Later, Marianne Späne moved to the pharmaceutical industry and joined the pharma division of Schweizerhalle as Head of the Sales and Marketing department. Subsequently, she joined Aceto, a US-based company, where she developed European expansion strategies.

Marianne Späne holds degrees in finance, business administration and marketing from the Business Management School (KFS) in Basel and the Marketing & Business School in Zurich (MBSZ).

Marianne Späne is a German citizen.

Wolfgang Wienand, Ph.D., Chief Scientific and Strategy Officer

With effect of May 1, 2017, Wolfgang Wienand leads Siegfried’s global Research & Development activities. In addition to this role he continues to be responsible for Strategy, Mergers & Acquisitions, Legal, Intellectual Property and Regulatory Affairs Management. Wolfgang Wienand joined Siegfried in 2010 as Chief Scientific Officer and Head of Research & Development (until August 2012) before becoming Chief Strategy Officer and Head of Strategy and Mergers & Acquisitions in December 2011.

Before joining Siegfried, Wolfgang Wienand held senior management positions at Evonik Industries AG, formerly Degussa AG, mainly in the fields of fine chemicals and custom manufacturing for the pharmaceutical industry. At last he was responsible for strategy, business development and key account management of Evonik’s Advanced Silanes business with the photovoltaic and semiconductor industries.

Wolfgang Wienand studied chemistry at the Friedrich-Wilhelms University in Bonn and received his Ph.D. in organic and bioorganic chemistry from the University of Cologne, both in Germany. He also holds an executive master’s degree in international finance from HEC École des Hautes Études Commerciales de Paris, France.

Wolfgang Wienand is a German citizen.

to the top to top

Can't find the information
you are looking for?
Contact us

Siegfried AG
Untere Bruehlstrasse 4
CH-4800 Zofingen

Phone: +41 62 746 1111
Fax: +41 62 746 1202